Cardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study

Onco-hematological (OH) patients face significant cardiovascular risks due to malignancy and drug toxicity. Data are limited on the characteristics and outcomes of OH patients with cardiogenic shock (CS) in intensive care units (ICUs). This multicenter retrospective study included 214 OH patients with CS across 22 ICUs (2010−2021). The objectives were to (i) identify risk factors for 30-day mortality, (ii) describe early and long-term outcomes, and (iii) assess the prognostic impact of malignancy by comparing OH patients to a control group of CS patients. The 30-day survival rate was 44.8 %. Multivariate analysis identified previous cardiomyopathy (OR = 1.61), acute kidney injury (OR = 1.62), lactate levels (OR = 1.08 per 1 mmol/L), pulmonary embolism (OR = 3.04), invasive mechanical ventilation (OR = 3.48), and epinephrine use (OR = 2.09) as factors associated with 30-day mortality. Among ICU survivors, 54 % were alive at 1 year with a median left ventricular ejection fraction of 52 %. OH malignancy was significantly associated with 30-day mortality (HR 2.54). The prognosis for OH patients with CS in the ICU is poor, with epinephrine use associated with worse outcomes. Further research is needed to refine risk stratification and improve treatments for this population. [Display omitted] •This study represents the largest study focusing on onco-hematological (OH) patients with cardiogenic shock (CS) in ICU•It identifies key factors associated with higher 30-day mortality in OH patients with CS, such as epinephrine use.•It also shows that OH malignancy worsens CS outcomes compared to non-OH patients.•These findings suggest the need for tailored treatments in OH patients with CS, particularly limiting epinephrine use.